Caliway Biopharmaceuticals stock: CBL-514 trials move into Phase 3

Caliway Biopharmaceuticals' CBL-514 program is advancing through late-stage obesity research, according to a Medscape Medical News report published Friday, November 13, 2026. The report says the company's SUPREME-01 and SUPREME-02 Phase 3 trials are enrolling patients to evaluate CBL-514 for abdominal fat reduction.

CBL-514 is an investigational small-molecule injectable designed to induce apoptosis of adipocytes and reduce subcutaneous fat. Medscape said Phase 2 data showed statistically significant reductions in subcutaneous and visceral adipose tissue, based on MRI analyses from the CBL-0205 study presented at the European Association for the Study of Diabetes meeting.

Late-Stage Trials Set Milestones

The two pivotal studies are testing the candidate in abdominal fat reduction. Topline results from SUPREME-01 are expected in the second half of 2027, according to the report. The timetable leaves recruitment, trial execution and future clinical readouts as key milestones for the program.

Caliway is also expanding the potential use of CBL-514 beyond localized fat reduction. The U.S. Food and Drug Administration has cleared a Phase 2 study combining CBL-514 with tirzepatide in adults who are overweight or obese, Medscape reported. The combination program is intended to test the candidate alongside an established weight-management therapy.

The clinical updates concern investigational development. They do not represent regulatory approval or commercial availability of CBL-514.

Taiwan's TAIEX provides the relevant market context.

More news and analyses on Caliway Biopharmaceuticals stock